approxim
million
peopl
worldwid
persist
infect
hepat
c
viru
hcv
associ
chronic
inflamm
liver
emerg
lead
caus
fibrosi
cirrhosi
hepatocellular
carcinoma
vaccin
effect
hcv
addit
sever
side
effect
current
treatment
pegyl
plu
ribavirin
includ
depress
fatigu
symptom
haemolyt
anaemia
often
lead
discontinu
treatment
therebi
warrant
need
develop
novel
drug
higher
efficaci
favour
side
effect
profil
treat
hcv
infect
hepat
c
viru
envelop
rna
viru
belong
hepaciviru
genu
within
flavivirida
famili
genom
encod
singl
polyprotein
subsequ
cleav
host
viru
proteas
least
matur
individu
protein
four
structur
protein
c
six
nonstructur
protein
among
latter
promot
improp
upregul
hepat
nuclear
transcript
signal
pathway
lead
chronic
inflamm
prolifer
hepatoma
cell
induc
enzym
involv
product
variou
prostaglandin
pg
upon
exposur
multipl
stimuli
viral
bacteri
product
includ
lipopolysaccharid
cytokin
oncogen
mitogen
growth
factor
howev
aberr
upregul
express
contribut
progress
hepat
carcinogenesi
elev
pg
concentr
promot
cell
prolifer
surviv
inhibit
pathway
ultim
result
tumour
format
recent
variou
studi
report
elev
protein
level
favour
increas
hcv
replic
although
exact
mechan
remain
elucid
basi
find
attract
mean
minim
liver
malign
elimin
signal
pathway
simultan
reduc
viral
infect
hepatocarcinogenesi
shxt
commonli
use
tradit
chines
medicin
formula
compos
rhei
rhizoma
rheum
officinal
baill
scutellaria
radix
scutellaria
baicalensi
georgi
coptidi
rhizom
copti
chinensi
franch
shxt
possess
varieti
bioactiv
includ
hypotens
effect
effect
cardiovascular
effect
gastric
protect
antioxid
activ
neuron
protect
immunomodulatori
effect
shxt
use
clinic
treatment
human
diseas
hypertens
gastriti
gastric
bleed
peptic
ulcer
sever
year
current
number
studi
demonstr
shxt
herbal
compon
possess
antihepatocellular
carcinoma
activ
suggest
shxt
potenti
hepatoprotector
agent
sever
marker
compound
shxt
baicalin
wogonin
possess
antivir
activ
respiratori
syncyti
viru
rsv
hepat
b
viru
sever
acut
respiratori
syndrom
coronaviru
infect
influenza
viru
howev
date
activ
constitu
shxt
document
therefor
present
studi
assess
inhibitori
effect
hcv
replic
synergist
activ
combin
variou
inhibitor
use
hcv
replicon
system
extens
chemotherapeut
carcinogenesi
inhibitori
effect
shxt
extract
improp
induct
express
caus
hcv
replic
aetiolog
hcv
protein
evalu
find
may
contribut
better
treatment
regimen
patient
chronic
hcv
infect
dri
shxt
offer
sun
ten
pharmaceut
co
ltd
taipei
taiwan
three
tradit
chines
medicin
identifi
r
officinal
baicalensi
copti
chinesi
microscop
liquid
chromatographi
hplc
fingerprint
profil
sun
ten
pharmaceut
co
ltd
purchas
roch
ltd
san
francisco
ca
usa
telaprevir
purchas
toronto
research
chemic
inc
acm
bioscienc
belmont
ca
usa
respect
store
mm
dimethylsulphoxid
dmso
purchas
sigma
st
loui
mo
usa
final
concentr
dmso
reaction
maintain
constantli
experi
mixtur
r
officinal
baicalensi
c
chinesi
blend
ratio
total
kg
extract
three
time
use
meoh
meoh
extract
g
partit
ethyl
acet
ea
obtain
fraction
g
ea
fraction
g
fifti
gram
ea
fraction
subject
flash
column
chromatographi
elut
gradient
solvent
system
five
subfract
isol
thin
layer
chromatographi
among
subfract
g
isol
chromatographi
elut
gradient
solvent
system
seven
subfract
separ
chromatographi
final
fraction
term
approxim
mg
obtain
subfract
chromatographi
elucid
nuclear
magnet
reson
nmr
spectra
jasco
pump
jayte
bioscienc
ltd
hern
bay
kent
uk
jasco
detector
jayte
bioscienc
ltd
ascenti
lancast
uk
mm
column
supelco
employ
hplc
analysi
isocrat
elut
perform
vv
flow
rate
mlmin
solvent
filter
filter
prior
use
eluent
detect
nm
data
analys
seri
version
softwar
shimadzu
kyoto
japan
purifi
fraction
verifi
activ
compon
isol
condit
describ
previous
collect
shown
fig
human
hepatoma
cell
cell
kindli
provid
dr
charl
rice
rockefel
univers
new
york
usa
cultur
dulbecco
modifi
eagl
medium
foetal
bovin
serum
nonessenti
amino
acid
cell
line
harbour
hcv
subgenom
replicon
rna
maintain
complet
media
contain
mgml
code
sequenc
amplifi
polymeras
chain
reaction
pcr
plasmid
contain
cdna
hcv
strain
clone
express
vector
invitrogen
carlsbad
ca
usa
design
promot
fragment
amplifi
human
genom
dna
describ
insert
promoterless
luciferas
vector
promega
co
madison
wi
usa
design
report
vector
measur
transcript
activ
stratagen
la
jolla
ca
usa
clone
dna
fragment
verifi
dna
sequenc
total
cellular
rna
isol
use
total
rna
miniprep
purif
kit
hopegen
biotechnolog
develop
enterpris
taiwan
accord
manufactur
instruct
northern
hybrid
perform
previous
describ
quantit
perform
measur
mrna
hcv
gapdh
previous
describ
infecti
hcv
particl
hcvcc
gener
transfect
genom
rna
cell
describ
cell
seed
densiti
cellswel
cultur
plate
infect
hcvcc
multipl
infect
h
follow
incub
variou
concentr
addit
h
subsequ
total
rna
collect
subject
measur
mrna
hcv
gapdh
describ
previous
western
blot
perform
describ
previous
membran
probe
either
antibodi
abcam
cambridg
usa
antibodi
genetex
ca
usa
antibodi
genetex
irvin
ca
usa
cell
viabil
determin
mt
assay
celltit
aqueou
one
solut
cell
prolifer
assay
system
promega
describ
previous
cell
treat
serial
dilut
combin
serial
dilut
uml
hcv
rna
polymeras
nucleosid
inhibitor
hcv
proteas
telaprevir
day
level
hcv
subgenom
rna
measur
quantit
previous
describ
multipl
drug
combin
data
determin
use
softwar
base
method
chou
talalay
biosoft
cambridg
uk
compar
singl
multipl
drug
determin
presenc
antagon
combin
index
ci
addit
ci
synerg
ci
ci
calcul
effect
concentr
present
herein
cell
transfect
plasmid
bd
bioscienc
clontech
palo
alto
ca
usa
use
reagent
biotechnolog
co
ltd
taipei
taiwan
accord
manufactur
instruct
parent
cell
cotransfect
togeth
transfect
complex
contain
secret
alkalin
phosphatas
seap
report
vector
serv
intern
control
normal
transfect
effici
transfect
cell
incub
variou
concentr
day
cell
lysat
prepar
luciferas
activ
use
luciferas
assay
system
promega
western
blot
analysi
follow
manufactur
instruct
cell
seed
plate
densiti
treat
variou
concentr
day
incub
cell
harvest
cell
membran
lyse
releas
intracellular
express
level
detect
immunosorb
assay
system
biotrak
amersham
bioscienc
accord
manufactur
protocol
data
present
mean
sd
least
three
independ
experi
statist
analysi
carri
student
consid
signific
base
fraction
isol
subfract
shxt
design
display
effect
inhibitori
action
hcv
protein
express
fig
lane
hplc
trace
shown
fig
accord
analysi
hplc
profil
nmr
spectra
major
compon
fraction
identifi
retent
time
found
min
ident
standard
hplc
condit
subsequ
major
peak
harbour
residu
eluent
harbour
two
minor
peak
individu
collect
examin
activ
base
calcul
peak
area
seri
version
softwar
shimadzu
amount
repres
respect
princip
standard
herbal
extract
cautious
prepar
base
fraction
marker
identifi
constitu
contribut
activ
cell
harbour
hcv
subgenom
rna
replicon
design
cell
treat
variou
elut
concentr
day
subsequ
cell
lysat
subject
western
blot
antibodi
level
gapdh
serv
load
control
shown
fig
lane
lane
significantli
inhibit
hcv
protein
synthesi
compar
mock
control
dmso
lane
inhibitori
effect
similar
effect
treatment
lane
contrast
treatment
sigma
exhibit
insignific
decreas
hcv
protein
level
lane
notabl
inhibitori
effect
hcv
protein
synthesi
conserv
combin
lane
confirm
contain
bioactiv
constitu
hcv
protein
synthesi
current
data
unabl
clearli
discrimin
individu
constitu
use
mixtur
investig
activ
report
treatment
equal
ratio
commerci
avail
serv
intern
control
experi
thu
elimin
biolog
interfer
activ
assay
confirm
antivir
activ
northern
blot
quantit
perform
specif
probe
primer
correspond
hcv
respect
level
cellular
gapdh
gene
serv
load
control
shown
fig
b
white
bar
clear
decreas
hcv
rna
level
occur
upon
treatment
day
compar
treatment
mock
control
cell
dmso
calcul
effect
concentr
defin
compound
concentr
reduc
hcv
rna
level
measur
analysi
b
hcv
replic
decreas
toxic
observ
b
white
bar
hcv
rna
level
remain
unchang
presenc
b
black
bar
cytotox
index
evalu
mt
cytotox
concentr
defin
compound
concentr
result
cell
death
c
yield
high
select
index
valu
si
similarli
activ
also
observ
hcv
infecti
system
valu
fig
white
bar
data
support
conclus
promis
agent
warrant
studi
next
investig
whether
combin
proteas
inhibitor
telaprevir
polymeras
inhibitor
would
produc
synergist
effect
inhibit
hcv
replic
cell
treat
combin
agent
variou
concentr
describ
materi
method
section
effect
combin
calcul
use
isobologram
method
comput
program
shown
tabl
combin
individu
inhibitor
synergist
inhibit
hcv
replic
reveal
ci
valu
rang
appar
cytotox
observ
test
concentr
combin
mt
analysi
prevent
effect
standard
shxt
report
abl
inhibit
gene
express
includ
prostaglandin
product
test
whether
express
influenc
cell
transfect
plasmid
carri
firefli
luciferas
driven
promot
day
presenc
increas
concentr
shown
fig
reduct
luminesc
signal
observ
cell
compar
cell
white
bar
parent
cell
fold
control
treatment
signific
effect
gene
express
black
bar
subsequ
western
blot
perform
confirm
effect
suppress
express
consist
result
report
assay
reduc
protein
level
manner
fig
contrast
result
signific
reduct
protein
level
fig
addit
activ
presenc
quantifi
use
biotrak
enzym
immunoassay
result
show
level
decreas
manner
fig
activ
one
ubiquit
mediat
activ
viral
infect
therefor
perform
assay
determin
whether
suppress
relat
modul
transcript
factor
upon
treatment
cell
transient
transfect
plasmid
follow
transfect
cell
incub
without
day
shown
fig
luciferas
activ
assay
reveal
significantli
inhibit
transcript
activ
manner
white
bar
support
possibl
suppress
may
involv
effect
expect
affect
transcript
activ
black
bar
hepat
c
viru
protein
shown
oncogen
potenti
link
stimul
express
differ
mechan
examin
whether
abl
block
express
prevent
hepatocarcinogenesi
express
vector
cotransfect
report
vector
parent
cell
absenc
presenc
transfect
alon
serv
basal
promot
activ
day
luciferas
activ
measur
shown
fig
markedli
inhibit
promot
activ
manner
white
bar
inhibit
promot
activ
induc
black
bar
subsequ
extend
studi
examin
whether
inhibitori
effect
mediat
activ
plasmid
cotransfect
promot
plasmid
cell
absenc
presenc
day
transfect
alon
serv
basal
promot
activ
result
luciferas
assay
show
promot
activ
markedli
suppress
manner
fig
white
bar
contrast
inhibit
promot
activ
black
bar
equal
express
condit
confirm
western
blot
analysi
use
antibodi
fig
b
b
c
data
show
effect
target
express
impli
potenti
prevent
hepatocarcinogensi
studi
extend
bioactiv
shxt
hcv
caus
agent
hepatocarcinogensi
demonstr
activ
extract
deriv
herbal
medicin
shxt
possess
effect
activ
fig
analys
bioactiv
constitu
find
major
compon
signific
activ
concentr
fig
consist
result
recent
obtain
li
et
al
demonstr
singl
show
neglig
inhibitori
effect
hcv
replic
even
high
concentr
approxim
format
dimer
design
procyanidin
requisit
activ
howev
observ
controversi
taken
observ
report
takeshita
et
al
demonstr
catechin
extract
blueberri
leaf
suppress
hcv
rna
synthesi
diverg
result
may
attribut
differ
geometr
isom
catechin
isol
studi
takeshita
et
al
studi
develop
effect
treatment
option
improv
sustain
virolog
respons
toler
treatment
durat
sever
antivir
agent
telaprevir
hcv
proteas
inhibitor
nucleosid
hcv
polymeras
inhibitor
examin
clinic
trial
howev
increas
drug
resist
becom
obstacl
success
therapeut
intervent
present
studi
provid
effect
safe
extract
synergist
inhibit
hcv
replic
combin
chemotherapeut
agent
hcv
replicon
system
tabl
could
greatli
reduc
potenti
resist
side
effect
includ
combin
therapi
aetiolog
protein
hcv
includ
structur
protein
core
nonstructur
protein
particularli
markedli
modul
activ
appear
turn
promot
hcv
replic
recent
downregul
express
consid
molecular
mechan
involv
inhibitori
effect
hcv
replic
use
select
inhibitor
includ
acetylsalicyl
acid
inhibitor
iii
whether
activ
depend
downregul
investig
addit
modul
activ
shown
increas
replic
number
virus
cytomegaloviru
herpesviru
rsv
enteroviru
although
detail
mechan
clearli
defin
moreov
also
found
tumour
necrosi
factor
tnf
activ
promot
also
inhibit
data
shown
consequ
block
pathway
fig
also
may
provid
potenti
agent
chemoprevent
viru
infect
conclus
first
demonstr
effect
inhibit
hcv
replic
display
synergist
activ
combin
variou
hcv
inhibitor
moreov
inhibit
improp
induct
express
caus
either
hcv
replic
aetiolog
protein
therefor
may
serv
potenti
supplementari
treatment
patient
chronic
hepat
c
simultan
attenu
viral
replic
inflamm
carcinogenesi
close
correl
aberr
activ
express
work
support
nation
scienc
council
taiwan
grant
number
nsc
